16273B - en - 2012/07
ETEST APPLICATION GUIDE AEROBES ORGANISM
INOCULUM
SPECIFIC PHENOTYPE
MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
MHA
INCUBATION
0.5
3)
Suspension medium Saline
Time (h)
Cefoxitin (FX)
18-24h
Temperature/ Atmosphere 35 ± 2°C Ambient air
RECOMMENDED QUALITY CONTROL Strain Staphylococcus aureus S. aureus
COMMENTS 4) ®
ATCC 29213TM
≤ 4 mg/L
43300TM
> 4 mg/L
Mueller Hinton agar (MHA) + 2% NaCl
0.5-1
Saline
Oxacillin (OX) Amoxicillin/clavulanic acid (XL)
24h
35 ± 2°C Ambient air
S. aureus
43300TM
- Phenotype interpretation: OX ≥ 4 µg/mL and XL ≥ 8 µg/mL - Heavier inoculum improves detection of low level R
BORSA
MHA + 2% NaCl
0.5-1
Saline
Oxacillin (OX) Amoxicillin/clavulanic acid (XL)
24h
35 ± 2°C Ambient air
S. aureus
29213TM
- Phenotype interpretation: OX ≥ 4 µg/mL and XL ≤ 4 µg/mL
MRCNS
Mueller Hinton agar (MHA) + 2% NaCl
48h
35 ± 2°C Ambient air
43300TM
- Phenotype interpretation: OX ≥ 0.5 µg/mL - Heavier inoculum improves detection of low level R
MRSA
0.5-1
Saline
Oxacillin (OX)
S. aureus
Staphylococci
VISA/hVISA 1) Brain Heart Infusion (macromethod) agar (BHI) 1)
2
VISA/hVISA
0.5
VISA/VRSA (standard method)
MHA + 5% blood
MHA
0.5
BHI broth
Vancomycin (VA) Teicoplanin (TP) 1)
24h. Confirm at 48h
35 ± 2°C Ambient air
S. aureus QC ranges: TP = 0.5-2 µg/mL VA = 1-4 µg/mL
29213TM
- 0.1 mL inoculum/ 90mm plate - Phenotype interpretation: VA ≥ 8µg/mL and TP ≥ 8µg/mL, OR TP ≥12 µg/mL (alone) = VISA/hVISA - Confirm VISA/hVISA by PAP
BHI broth
Etest GRD2) (Vancomycin (VA) / Teicoplanin (TP) 1))
18-24h. Confirm at 48h
35 ± 2°C Ambient air
S. aureus S. aureus S. aureus
29213TM 700698TM 700699TM
- Confirm VISA/hVISA by PAP
24h
35 ± 2°C Ambient air
Saline
Vancomycin (VA)
bioMérieux SA
English - 1
S. aureus
TM
29213
- Phenotype interpretation: VA ≥ 4µg/mL = VISA VA ≥ 16µg/mL = VRSA (CLSI)
®
Etest Application Guide
ORGANISM
16273B - en - 2012/07
INOCULUM
SPECIFIC PHENOTYPE
MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
MRSA Secondary panel
MHA
0.5
Suspension medium
MHA
MHA
0.5
0.5
Time (h)
Temperature/ Atmosphere
RECOMMENDED QUALITY CONTROL Strain
COMMENTS 4) ®
ATCC
Saline
Clindamycin (CM) Daptomycin (DPC) Linezolid (LZ) Vancomycin (VA) Teicoplanin (TP) 1) Quinupristin/dalfopristin (QDA) Rifampicin (RI) 1)
16-20h. VA and TP full 24h
35 ± 2°C Ambient air
S. aureus
29213TM
Saline
Benzylpenicillin (PG) Erythromycin (EM) Linezolid (LZ) Trimethoprim/sulfamethoxazole (TS) Vancomycin (VA) Teicoplanin (TP) 1) Ciprofloxacin (CI)
16-20h. VA and TP full 24h
35 ± 2°C Ambient air
S. aureus
29213TM
Saline
Ampicillin (AM) Daptomycin (DPC) Linezolid (LZ) Quinupristin/dalfopristin (QDA) Vancomycin (VA) Teicoplanin (TP) 1) Minocycline (MC)
16-20h. Confirm VA and TP at 24h
35 ± 2°C Ambient air
E. faecalis
29212TM
Staphylococci Non-MRSA secondary panel
INCUBATION 3)
Enterococci
HLAR
MHA
MHA
0.5-1
0.5 (1 for mucoid organisms)
MHA
0.5 (1 for mucoid organisms)
29212TM
35 ± 2°C Ambient air
Escherichia coli E. coli
25922TM 35218TM (PTc) 35218TM 700603TM
35 ± 2°C Ambient air
E. coli Klebsiella pneumoniae (ESBL positive) Pseudomonas aeruginosa
Saline
24h. Confirm SM at 48h
35 ± 2°C Ambient air
Saline
Gentamicin (GM) Piperacillin/ tazobactam (PTc) Cefepime (PM) Ciprofloxacin (CI) Imipenem (IP) Aztreonam (AT)
16-20h
Saline
Cefotaxime/cefotaxime + clavulanic acid (CT/CTL) Ceftazidime/ceftazidime + clavulanic 16-20h acid (TZ/TZL) Cefepime/cefepime + clavulanic acid (PM/PML) 1)
Enterobacteriaceae
ESBL
E. faecalis QC ranges: GM = 4-16 µg/mL SM = 64–256 µg/mL
Gentamicin (GM) high range Streptomycin (SM) high range 1)
bioMérieux SA
English - 2
27853TM
- Heavier inoculum preferable - SM > 1024 µg/mL or GM > 512 µg/mL = positive HLAR (CLSI) - SM > 512 µg/mL or GM > 128 µg/mL = positive HLAR (EUCAST)
- Investigate ND results by an alternative method
®
Etest Application Guide
ORGANISM
16273B - en - 2012/07
INOCULUM
SPECIFIC PHENOTYPE
MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
MBL MP/MPI 1)
MHA
0.5 (1 for mucoid organisms)
Suspension medium Saline
Time (h) Meropenem/Meropenem +EDTA (MP/MPI)
16-20h.
Temperature/ Atmosphere
MHA
0.5
MHA
0.5 (1 for mucoid organisms)
MHA
0.5 (1 for mucoid organisms)
MBL IP/IPI
MHA
0.5 (1 for mucoid organisms)
K. pneumoniae K. pneumoniae
700603TM - Investigate ND results by BAA-2146TM an alternative method 700603TM
35 ± 2°C Ambient air
Klebsiella pneumoniae (negative) K. pneumoniae (positive)
27853TM 35218TM (PTc)
16-20h
Saline
Ceftazidime (TZ) Gentamicin (GM) Aztreonam (AT) Ciprofloxacin (CI) Imipenem (IP) Piperacillin/tazobactam (PTc)
16-20h. 48h for slow growers
35 ± 2°C Ambient air
P. aeruginosa E. coli
Saline
16-20h. Imipenem/imipenem + EDTA (IP/IPI) 48h for slow growers
35 ± 2°C Ambient air
P. aeruginosa 27853TM (negative) Stenotrophomonas 13636TM maltophilia (positive)
Saline
Ceftazidime (TZ) Meropenem (MP) Amikacin (AK) Ampicillin/sulbactam (AB) Levofloxacin (LE) Minocycline (MC)
20-24h. 48h for slow growers
35 ± 2°C Ambient air
P. aeruginosa E. coli
MHA
0.5 (1 for mucoid organisms)
Saline
16-20h. Imipenem/imipenem + EDTA (IP/IPI) 48h for slow growers
35 ± 2°C Ambient air
P. aeruginosa 27853TM (negative) Stenotrophomonas 13636TM maltophilia (positive)
MHA
0.5 (1 for mucoid organisms)
Saline
Trimethoprim/sulfamethoxazole (TS) Ceftazidime (TZ) Levofloxacin (LE) Meropenem (MP) Minocycline (MC)
20-24h. 48h for slow growers
35 ± 2°C Ambient air
E. coli
25922TM
MHA
0.5 (1 for mucoid organisms)
Saline
Trimethoprim/sulfamethoxazole (TS) Ceftazidime (TZ) Levofloxacin (LE) Minocycline (MC) Ticarcillin/clavulanic acid (TLc)
20-24h. 48h for slow growers
35 ± 2°C Ambient air
E. coli E. coli
25922TM 35218TM (TLc)
Acinetobacter spp.
MBL IP/IPI
Burkholderia cepacia
Stenotrophomonas maltophilia
1)
ATCC
Cefotetan/Cefotetan + Cloxacillin (CN/CNI)
Saline
Pseudomonas spp.
1)
Strain
COMMENTS 4) ®
35 ± 2°C Ambient air
Enterobacteriaceae AmpC 2)
RECOMMENDED QUALITY CONTROL
INCUBATION 3)
bioMérieux SA
English - 3
TM
BAA-1144
- Investigate ND results by an alternative method
- Investigate ND results by an alternative method
27853TM 35218TM (AB)
- Investigate ND results by an alternative method
®
Etest Application Guide
16273B - en - 2012/07
FASTIDIOUS ORGANISMS ORGANISM
SPECIFIC PHENOTYPE
INOCULUM MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
Pneumococci
MHA + 5% blood (CLSI) MHF (EUCAST)
0.5 (1 for mucoid organisms)
Suspension medium
Time (h)
20-24h
35 ± 2°C 5% CO2
Streptococcus pneumoniae
49619TM
MH broth or BHI broth
Benzylpenicillin (PG) Cefotaxime (CT) Chloramphenicol (CL) Ofloxacin (OF) Linezolid (LZ) 1) Vancomycin (VA) Daptomycin (DPC)
20-24h
35 ± 2°C 5% CO2
S. pneumoniae
49619TM
20-24h
35 ± 2°C 5% CO2
5)
5)
35 ± 2°C 5% CO2
Haemophilus influenzae H. influenzae
49247TM
20-24h
20-24h
35 ± 2°C 5% CO2
Abiotrophia & Granulicatella spp. 1)
MH chocolate agar + 0.001% pyridoxal HCl + 1 0.01% cysteine
Broth (MH broth or BHI broth)
Haemophilus influenzae
Haemophilus Test Media (HTM) (CLSI) MHF (EUCAST)
0.5 (1 for mucoid organisms)
MH broth or HTM broth (or BHI broth)
Moraxella catarrhalis 1)
MHA + 5% blood (CLSI) MHF (EUCAST)
0.5
MH broth or BHI broth
1
Metronidazole (MZ) Brucella broth Clindamycin (CM) or MH broth Cefoxitin (FX) (or Schaedler Imipenem (IP) Broth + vit K3) Piperacillin/tazobactam (PTc) Benzylpenicillin (PG)
Amoxicillin/ clavulanic acid (XL) Cefotaxime (CT) Meropenem (MP) Trimethoprim/sulfamethoxazole (TS) Chloramphenicol (CL)
bioMérieux SA
English - 4
24-72h (48h for CM). 35 ± 2°C Confirm all Anaerobic S results at system 48h.
5)
COMMENTS 4)
ATCC®
Strain
MH broth or BHI broth
MHA + 5% blood (CLSI) MHF (EUCAST)
Anaerobes
Temperature/ Atmosphere
Meropenem (MP) Cefotaxime (CT) Benzylpenicillin (PG) Clindamycin (CM) 1) Vancomycin (VA) Trimethoprim/sulfamethoxazole (TS)
Streptococci
Brucella agar + 5% blood + vitamin K (1 µg/mL) + hemin (5 µg/mL) (BBA) (CLSI)
0.5 (1 for mucoid organisms)
RECOMMENDED QUALITY CONTROL
INCUBATION 3)
49766TM (MP, XM) 5)
Bacteroides fragilis 25285TM B. thetaiotaomicron 29741TM Eubacterium lentum 43055TM
- For obligate anaerobes, ensure anaerobic conditions are maintained throughout processing - DO NOT VORTEX - Anaerobiosis must be achieved within 1-2 hours for MZ
®
Etest Application Guide
ORGANISM
16273B - en - 2012/07
SPECIFIC PHENOTYPE
INOCULUM MEDIA
6)
INCUBATION SUGGESTED MIC PANEL
McF equivalent
3)
Suspension medium
Time (h)
Gonococci
MH broth (or BHI broth)
Ciprofloxacin (CI) Benzylpenicillin (PG) Tetracycline (TC) Ceftriaxone (TX) Spectinomycin (SC) 1)
20-24h
Meningococci 1)
MHA + 5% blood (CLSI) MH chocolate agar
Broth (BHI broth)
Ciprofloxacin (CI) Benzylpenicillin (PG) Trimethoprim/sulfamethoxazole (TS) Meropenem (MP) Ceftriaxone (TX)
24h
Campylobacter spp. 1)
MHA + 5% blood (CLSI) MHF (EUCAST)
0.5
1
43504TM
35 ± 2°C 5% CO2
Neisseria gonorrhoeae
49226TM
- 3-4 strips max./150mm plate to facilitate reading
35 ± 2°C 5% CO2
S. pneumoniae E. coli
49619TM 25922TM
- Work in BSC
33560TM
- 3-4 strips max./150mm plate to facilitate reading - Do not invert plate - Campylobacter colonies may be translucent and difficult to see. Tilt plate and use oblique light to read endpoint.
35 ± 2°C Microaerophilic, 72h or longer except MZ first 24h anaerobic
Supplemented GC agar (CLSI) 0.5 MH chocolate agar
Broth (BHI broth)
Ciprofloxacin (CI) Gentamicin (GM) Erythromycin (EM) Doxycycline (DC)
bioMérieux SA
48-72h
English - 5
ATCC
Helicobacter pylori
Amoxicillin (AC) Clarithromycin (CH) Metronidazole (MZ) Tetracycline (TC)
MHA + 5% blood (≥ 2 weeks old) (CLSI)
Strain
COMMENTS 4) ®
- 1 strip/90mm plate - Strip handle to be placed at edge of plate. - H. pylori colonies are pin-point, translucent and difficult to see. Tilt plate and use oblique light to read endpoint.
MH broth + 5% serum or BHI broth + 5% serum
Helicobacter pylori 1)
3
Temperature/ Atmosphere
RECOMMENDED QUALITY CONTROL
35 ± 2°C Microaerophilic
Campylobacter jejuni
®
Etest Application Guide
16273B - en - 2012/07
FASTIDIOUS GRAM-POSITIVE ORGANISMS 1) ORGANISM
SPECIFIC PHENOTYPE
INOCULUM MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
Arcanobacterium spp., Listeria monocytogenes*, Erysipelothrix, Lactobacillus, Corynebacterium, Bacillus spp., Rothia, Pediococcus*, Leuconostoc*, and Gemella spp.*
MHA + 5% blood (CLSI) * MHF (EUCAST)
1
RECOMMENDED QUALITY CONTROL
INCUBATION
Suspension medium
3)
Time (h)
Broth (BHI broth)
Temperature/ Atmosphere
20-24h (48h if 35 ± 2°C required) 5% CO2
bioMérieux SA
English - 6
ATCC®
Strain
5)
5)
COMMENTS 4)
®
Etest Application Guide
16273B - en - 2012/07
FASTIDIOUS GRAM-NEGATIVE ORGANISMS 1) ORGANISM
INOCULUM
SPECIFIC PHENOTYPE
MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
Suspension medium
1
Broth (BHI broth)
Bordetella pertussis
Regan-Lowe Bordet-Jengou or MHA + 5% blood
Capnocytophaga spp.
Time (h)
Temperature/ Atmosphere
3-5 days
35 ± 2°C 5% CO2
3
Broth (BHI broth)
3-5 days
35 ± 2°C Ambient air in bags, moist
BBA
1
Broth (BHI broth)
48h
35 ± 2°C 5% CO2
Legionella spp.
Buffered Charcoal Yeast Extract (BCYE)
1
Broth (BHI broth)
3-5 days
35 ± 2°C 5% CO2
Pasteurella spp.
MHA + 5% blood (CLSI) MHF (EUCAST)
1
Broth (BHI broth)
48h
35 ± 2°C 5% CO2
Francisella tularensis
Cysteine Heart Agar + 10% blood 1) (or + 2% haemoglobin 3)) alternatively, Glucose Cysteine Blood Agar
1
Suspend 48h colonies from chocolate agar in broth (BHI broth)
Clindamycin (CM) Tetracycline (TC) Ciprofloxacin (CI) Gentamicin (GM)
48-72h
37 ± 2°C 5% CO2
HACEK group
MHA + 1% haemoglobin + 1% IsoVitalex or HTM or BBA
1
Broth (BHI broth)
Levofloxacin (LE) Imipenem (IP) Trimethoprim/sulfamethoxazole (TS) Ceftriaxone (TX)
24-72h
35 ± 2°C 5% CO2
Bartonella spp.
MH chocolate agar
RECOMMENDED QUALITY CONTROL
INCUBATION 3)
bioMérieux SA
English - 7
COMMENTS 4)
ATCC®
Strain 5)
5)
5)
5)
5)
5)
5)
5)
5)
5)
5)
5)
H. influenzae H. influenzae
49247TM 49766TM (IP)
- Testing should only be performed in appropriate reference laboratories. - Perform all work within BSC Class IIA and minimum BSL 2 environment.
®
Etest Application Guide
16273B - en - 2012/07
MYCOBACTERIA AND AEROBIC ACTINOMYCETES 1) ORGANISM
SPECIFIC PHENOTYPE
INOCULUM MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
Mycobacterium tuberculosis
Nontuberculous mycobacteria
Rapid growing mycobacteria
Nocardia spp.
Middlebrook 7H11 + 10% OADC agar
MHA + 10% OADC + 5% blood (M. kansasii use same agar as for MTB)
MHA + 5% blood
MHA + 5% blood
INCUBATION
Suspension medium
Time (h)
M7H9 broth + 0.5% tween + 2% glycerol Vortex with sterile glass beads 3-5 mins, settle 20 mins & adjust supernatant to correct turbidity.
Ethambutol (EB) Ethionamide (ET) Isoniazide (IZ) Rifampicin (RI)
M7H9 broth Vortex with sterile glass beads 3-5 mins, settle 20 mins & adjust supernatant to correct turbidity.
Amikacin (AK) Ciprofloxacin (CI) Clarithromycin (CH) Rifampicin (RI)
1
1
3-4
1 (3 for M. kansasii)
3)
Temperature/ Atmosphere
RECOMMENED QUALITY CONTROL Strain
COMMENTS 4)
ATCC®
37 ± 2°C 5-10% CO2
Mycobacterium tuberculosis M. tuberculosis
27294TM AW388 (not ATCC)
- Pre-incubation 24h - 1 strip/90mm plate, seal plates - Perform all work within BSC class IIA
5-10 days
35 ± 2°C (M. marinum at 30°C) 5% CO2
M. avium M. avium spp. avium M. marinum M. kansasii
700898TM 35713TM 927TM 12478TM
- 1 strip/90mm plate, seal plates - Antibiogram is species specific
Saline
Cefoxitin (FX) Imipenem (IP) Ciprofloxacin (CI) Clarithromycin (CH)
48-72h
30-35°C Ambient air, moist
M. fortuitum M. peregrinum
6841TM 700686TM
- Subculture twice before preparing inoculum - 3-4 strips max./150mm plate to facilitate reading
Broth (BHI broth)
Amikacin (AK) Trimethoprim/sulfamethoxazole (TS) Ciprofloxacin (CI) Clarithromycin (CH) Imipenem (IP)
48-72h (dependent on spp.)
35 ± 2°C Ambient air
S. aureus
29213TM
bioMérieux SA
5-10 days
English - 8
®
Etest Application Guide
16273B - en - 2012/07
FUNGI ORGANISM
SPECIFIC PHENOTYPE
INOCULUM MEDIA
6)
SUGGESTED MIC PANEL McF equivalent
Suspension medium
Yeast
RPMI 1640 + 2% glucose + MOPS + 1.5% Bacto agar
0.5 (1 for Cryptococcus neoformans)
Mould 1)
RPMI 1640 + 2% glucose + MOPS + 1.5% Bacto agar
0.5 Aspergillus spp. Saline + (1 for Fusarium, Tween 20 Rhizopus spp.)
Saline
RECOMMENDED QUALITY CONTROL
INCUBATION 3)
Time (h)
Temperature/ Atmosphere
Strain
COMMENTS 4)
ATCC®
Fluconazole (FL) Itraconazole (IT) Amphotericin B (AP) 1) Flucytosine (FC) Voriconazole (VO) Caspofungin (CS) 1)
35 ± 2°C 24-48h. Ambient air 48-72h for in bags, C. neoformans moist
Candida albicans C. krusei C. parapsilosis
90028TM 6258TM 22019TM
Amphotericin B (AP) 1) Itraconazole (IT) Voriconazole (VO) 1) Posaconazole (POS) 1) Caspofungin (CS) 1)
16-72h (Dependent on genus)
35 ± 2°C Ambient air in bags, moist
C. parapsilosis Aspergillus flavus A. fumigatus
22019TM 204304TM 204305TM
- Once plate inoculated, re-dip swab and streak again.
1) In the USA, For Research Use Only (RUO). The contents of this document do not in any way indicate or imply new in vitro diagnostic uses of Etest, outside those which are FDA-cleared for certain antibiotics and organism groups. 2) Worldwide, For Research Use Only (RUO). 3) Example based on CLSI®, Performance Standards for Antimicrobial Susceptibility Testing supplement M100-S. Please use your own selection of MIC panels. 4) Additional Etest information is available at www.biomerieux.com/techlib. 5) For QC of fastidious organisms, please refer to local recommendations and/or CLSI M45-A Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. 6) For media available in the bioMérieux range, see page 10 (consult www.biomerieux.com/techlib for availability of certificates of compatibility). KEY: BORSA BSC ESBL HLAR MBL MRCNS MRSA ND OADC PAP VISA/hVISA
Borderline ORSA (non-mec A resistance) due to type A macro-inducible ß-lactamase inhibited by clavulanic acid Biological Safety Cabinet Extended Spectrum ß-Lactamase High-Level Aminoglycoside Resistance Metallo ß-Lactamase Methicillin-Resistant Coagulase-Negative Staphylococci (mec A+) Methicillin-Resistant Staphylococcus aureus (mec A+) Non-Determinable Oleic acid, Albumin, Dextrose Complex Population Analysis Profile Vancomycin Intermediate/ hetero-Intermediate Staphylococcus aureus
bioMérieux SA
English - 9
®
Etest Application Guide
16273B - en - 2012/07
MEDIA AVAILABLE IN THE BIOMERIEUX RANGE Consult the bioMerieux Technical Library (www.biomerieux.com\techlib) for availability of certificates of compatibility For non-fastidious bacteria: • Mueller Hinton 2 agar bioMérieux Ref. 43301/43309 - 20 / 100 plates 90 mm bioMérieux Ref. 43302 - 20 plates 145 mm bioMérieux Ref. 43511 - 20 plates 120 x 120 mm bioMérieux Ref. 41864 - 6 x 200 ml bioMérieux Ref. 51075 - 500 g
For fastidious bacteria: EUCAST recommendation: • Mueller Hinton 2 horse blood NAD agar bioMérieux Ref. 43901/43919 - 20 / 100 plates 90 mm bioMérieux Ref. 43904 - 20 plates 120 x 120 mm CLSI recommendation: • Mueller Hinton 2 sheep blood agar bioMérieux Ref. 43321/43329 - 20 / 100 plates 90 mm bioMérieux Ref. 43324 - 20 plates 120 x 120 mm
For anaerobes: • Brucella blood agar (with Vitamin K1 + Hemin) bioMérieux Ref. 411 968 - 20 plates 90 mm
For fungi and yeasts: • RPMI agar bioMérieux Ref. AEB 122 180 - 10 plates 90 mm bioMérieux Ref. AEB 122 182 - 10 plates 140 mm
SUSPENSION MEDIA AVAILABLE IN THE BIOMERIEUX RANGE • Brain-Heart Infusion broth bioMérieux Ref. 42081 - 20 x 9 ml
• API® NaCl 0.85 % Medium (saline) bioMérieux Ref. 20070 – 100 x 2ml bioMérieux Ref. 20040 – 100 x 3ml bioMérieux Ref. 20230 – 100 x 5ml
• Schaedler Broth + vit. K3 bioMérieux Ref. 42106 - 20 x 13 ml
BIOMERIEUX, the blue logo, API and Etest are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies. CLSI is a registered trademark belonging to Clinical and Laboratory Standards Institute, Inc. The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection. Any other name or trademark is the property of its respective owner.
bioMérieux SA Chemin de l'Orme 69280 Marcy-l'Etoile - France
RCS LYON 673 620 399 Tel. 33 (0)4 78 87 20 00 Fax 33 (0)4 78 87 20 90 www.biomerieux.com